Denis Viglietti

Denis Viglietti

Auto-generated profile, based on publicly available information

Denis Viglietti

AURA (Association pour l'Utilisation du rein Artificiel en Région Parisienne), 75014 Paris, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ABAntoine Bouquegneau
Antoine Bouquegneau
CLCharlotte Loheac
Charlotte Loheac
OAOlivier Aubert
Olivier Aubert
YBYassine Bouatou
Yassine Bouatou
DVDenis Viglietti
Denis Viglietti
ALAlexandre Loupy
Alexandre Loupy
Anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) are recognized as a major barrier to patients’ access to organ transplantation and the major cause of graft failure. The capacity of circulating anti-HLA DSAs to activate complement has been suggested as a potential biomarker for optimizing graft allocation and improving the rate of successful transplantations. To address the clinical relevance of complement-activating anti-HLA DSAs across all solid organ transplant patients, we performed a meta-analysis of their association with transplant outcome through a systematic review, from inception to January 31, 2018. The primary outcome was allograft loss, and the secondary outcome was allograft rejection. A comprehensive search strategy was conducted through several databases (Medline, Embase, Cochrane, and Scopus). A total of 5,861 eligible citations were identified. A total of 37 studies were included in the meta-analysis. Studies reported on 7,936 patients, including kidney (n = 5,991), liver (n = 1,459), heart (n = 370), and lung recipients (n = 116). Solid organ transplant recipients with circulating complement-activating anti-HLA DSAs experienced an increased risk of allograft loss (pooled HR 3.09; 95% CI 2.55–3.74, P = 0.001; I2 = 29.3%), and allograft rejection (pooled HR 3.75; 95% CI: 2.05–6.87, P = 0.001; I2 = 69.8%) compared to patients without complement-activating anti-HLA DSAs. The association between circulating complement-activating anti-HLA DSAs and allograft failure was consistent across all subgroups and sensitivity analyses. Limitations of the study are the observational and retrospective design of almost all included studies, the higher proportion of kidney recipients compared to other solid organ transplant recipients, and the inclusion of fewer studies investigating allograft rejection. In this study, we found that circulating complement-activating anti-HLA DSAs had a significant deleterious impact on solid organ transplant survival and risk of rejection. The detection of complement-activating anti-HLA DSAs may add value at an individual patient level for noninvasive biomarker-guided risk stratification. National Clinical Trial protocol ID: NCT03438058.

12 February 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
YBYassine Bouatou
Yassine Bouatou
DVDenis Viglietti
Denis Viglietti
DPDaniele Pievani
Daniele Pievani
KLKevin Louis
Kevin Louis
JHJean-Paul Duong Van Huyen
Jean-Paul Duong Van Huyen
CLCarmen Lefaucheur
Carmen Lefaucheur
The recent recognition of complex and chronic phenotypes of T cell‐mediated rejection (TCMR) has fostered the need to better evaluate the response of acute TCMR − a condition previously considered to lack relevant consequences for allograft survival − to the standard of care. In a prospective cohort of kidney recipients (n=256) with biopsy‐proven acute TCMR receiving corticosteroids, we investigated clinical, histological and immunological phenotypes at the time of acute TCMR diagnosis and 3 months posttreatment. Independent posttreatment determinants of allograft loss included the glomerular filtration rate (GFR) (HR=0.94; 95%CI=0.92‐0.96; p<0.001), proteinuria (HR=1.40; 95%CI=1.10‐1.79; p=0.007), time since transplantation (HR=1.02; 95%CI=1.00‐1.03; p=0.016), peritubular capillaritis (HR=2.27; 95%CI=1.13‐4.55; p=0.022), interstitial inflammation in sclerotic cortical parenchyma (i‐IF/TA) (HR=1.87; 95%CI=1.08‐3.25; p=0.025) and donor‐specific anti‐HLA antibodies (DSAs) (HR=2.67; 95%CI=1.46‐4.88; p=0.001). Prognostic value was improved using a composite evaluation of response to treatment vs clinical parameters only (cNRI=0.68; 95%CI=0.41‐0.95; p<0.001). A classification tree for allograft loss identified five patterns of response to treatment based on the posttreatment GFR, i‐IF/TA and anti‐HLA DSAs (cross‐validated accuracy=0.80). Compared with responders (n=155, 60.5%), nonresponders (n=101, 39.5%) had a higher incidence of de novo DSAs, antibody‐mediated rejection and allograft loss at ten years (p<0.001 for all comparisons). Thus, clinical, histological and immunological assessment of response to treatment of acute TCMR revealed different profiles of the response to treatment with distinct outcomes.

7 June 2025 in Bulletin de la Dialyse à Domicile
Verified
Journal Article
Open access
PDF file
PUPablo Antonio Ureña-Torres
Pablo Antonio Ureña-Torres
DVDenis Viglietti
Denis Viglietti
Ziad A. MassyZiad A. Massy
Ziad A. Massy
Calciphylaxis is a rare and potentially fatal disease manifested by progressive skin ulcerations due to calcification and obstruction of small-caliber arteries and arterioles. It mainly affects patients with chronic kidney disease treated by dialysis or renal transplantation but also individuals with normal kidney function, in which case it is often associated with chronic inflammatory diseases, neoplasia, primary hyperparathyroidism, and post-bariatric surgery. Necrotized ulcerations can become infected, leading to septic syndrome and a mortality rate of up to 80%. Its incidence varies from one case per 1,000 to one case per 1,500 hemodialysis patients per year, although this is probably underestimated. Clinical manifestations include very painful nodular or plaque-like indurations occurring in the extremities and central to the body. Lesions can also affect the fingers, penis, breasts, and visceral organs such as the lungs, intestines, and eyes. Its management is complex and requires a multimodal, individualized approach, involving close cooperation between nephrologists, dermatologists, surgeons, and other specialists. The aim of this review is to revise old and new aspects of this management while including the control of parameters of mineral and bone metabolism disorders, the replacement of vitamin K antagonists by alternative anticoagulants, the optimization of dialysis prescription, and the use of sodium thiosulfate, as well as new experimental therapies under development. We hope this review will help avoid common pitfalls and provide the highest quality care for patients with calciphylaxis.